Mucosal Healing in Inflammatory Bowel Disease: Where Do We Stand?

Curr Gastroenterol Rep. 2010 Dec;12(6):471-8. doi: 10.1007/s11894-010-0146-8.

Abstract

The definition of remission in Crohn's disease and ulcerative colitis has evolved to include mucosal healing as a measure of treatment efficacy. Randomized, controlled trials have demonstrated mucosal healing is attainable with the current arsenal of therapies available to treat inflammatory bowel disease. Mucosal healing has been shown to reduce the likelihood of clinical relapse, reduce the risk of future surgeries, and reduce hospitalizations. This review focuses on the latest studies addressing clinical outcomes of mucosal healing in the clinical trial and practice setting.

Publication types

  • Review

MeSH terms

  • Adalimumab
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Colitis, Ulcerative / drug therapy
  • Colitis, Ulcerative / pathology*
  • Crohn Disease / drug therapy
  • Crohn Disease / pathology*
  • Endoscopy, Gastrointestinal
  • Feces / chemistry
  • Humans
  • Infliximab
  • Intestinal Mucosa / pathology*
  • Lactoferrin / administration & dosage
  • Leukocyte L1 Antigen Complex / administration & dosage

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Leukocyte L1 Antigen Complex
  • Infliximab
  • Lactoferrin
  • Adalimumab